

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/563,731
	Filing Date	January 6, 2006
	First Named Inventor	Else Agger
	Art Unit	1645
(Multiple sheets used when necessary)	Examiner	Nina Archie
SHEET 1 OF 1	Attorney Docket No.	PLOUG8.001APC

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	Gregoriadis, G. (1995) Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 13:527-537.	
	2	Hilgers et al. (1991) DDA as an immunological adjuvant. Res. Immunol. 143:494-503.	
	3	Koike et al. (1998) Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. 16(20):1982-1989	
	4	Moingeon et al. (2001) Towards the rational design of Th1 adjuvants. Vaccine. 19:4363-4372.	

8355497/bab/010810

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.